A placebo-controlled, randomized clinical trial comparing sertraline and imipramine for the treatment of dysthymia

Archives of General Psychiatry

Volumn 53, Issue 9, 1996, Pages 777-784

  Thase, Michael E ^a,i   Fava, Maurizio ^b   Halbreich, Uriel ^c   Kocsis, James H ^d   Koran, Lorrin ^e   Davidson, Jonathan ^f   Rosenbaum, Jerrold ^b   Harrison, Wilma ^g,h  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

^d WEILL CORNELL MEDICAL CENTER   (United States)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

^g The New York Presbyterian Hospital   (United States)

^h PFIZER INC   (United States)

ⁱ UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; IMIPRAMINE; PLACEBO; SERTRALINE;

ADULT; AGITATION; ANTICHOLINERGIC EFFECT; ANXIETY; ARTICLE; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSTHYMIA; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROTOXICITY; RANDOMIZED CONTROLLED TRIAL; RASH; SEXUAL DYSFUNCTION; SINGLE BLIND PROCEDURE; SOMNOLENCE;

EID: 0029834638     PISSN: 0003990X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpsyc.1996.01830090023004     Document Type: Article

References (44)

1. Weissman MM, Leaf PJ, Bruce ML, Florio L. The epidemiology of dysthymia in five communities: rates, risks, comorbidity, and treatment. Am J Psychiatry. 1988;145:815-819.
2. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry. 1994;51:8-19.
3. Markowitz JC, Moran ME, Kocsis JH, Frances AJ. Prevalence and comorbidity of dysthymic disorder among psychiatric outpatients. J Affect Disord. 1992;24:63-71.
4. Akiskal HS. Dysthymic disorder: psychopathology of proposed chronic depressive subtypes. Am J Psychiatry. 1983;140:11-20.
5. Wells KB, Stewart A, Hays RD, et al. The functioning and well-being of depressed patients: results from the Medical Outcomes Study. JAMA. 1989;262:914-919.
6. Friedman RA. Social impairment in dysthymia. Psychiatr Ann. 1993;23:632-637.
7. Kessler RC, Foster CL, Saunders WB, Stang PE. Social consequences of psychiatric disorders, I: educational attainment. Am J Psychiatry. 1995;152:1026-1032.
8. Keller MB, Shapiro RW. 'Double depression': superimposition of acute depressive episodes on chronic depressive disorders. Am J Psychiatry. 1982;139:438-442.
9. Zisook S. Treatment of dysthymia and atypical depression. J Clin Psychiatry Monogr. 1992;10:15-23.
10. Keller MB. The difficult depressed patient in perspective. J Clin Psychiatry. 1993;54(2 suppl):4-8.
11. Weissman MM, Klerman GL. The chronic depressive in the community: unrecognized and poorly treated. Compr Psychiatry. 1977;18:523-532.
12. Harrison WM, Stewart JW. Pharmacotherapy of dysthymic disorder. In: Kocsis JH, Klein DN, eds. Diagnosis and Treatment of Chronic Depression. New York, NY: Guilford Press; 1995:124-145.
13. Vallejo J, Gastro C, Catalan R, Salamero M. Double-blind study of imipramine versus phenelzine in melancholias and dysthymic disorders. Br J Psychiatry. 1987;151:639-651.
14. Rosenthal J, Hemlock C, Hellerstein DJ, et al. A preliminary study of serotonergic antidepressants in treatment of dysthymia. Prog Neuropsychopharmacol Biol Psychiatry. 1992;16:933-941.
15. Helleistein DJ, Yanowitch P, Rosenthal J, et al. A randomized double-blind study of fluoxetine versus placebo in the treatment of dysthymia. Am J Psychiatry. 1993;150:1169-1175.
16. Harrison W, Rabkin J, Stewart JW, et al. Phenelzine for chronic depression: a study of continuation treatment. J Clin Psychiatry. 1986;47:346-349.
17. 2 receptor antagonism in dysthymia disorder: a double-blind placebo-controlled study with ritanserin. Acta Psychiatr Scand. 1991;83:244-248.
18. Bakish D, Lapierre YD, Weinstein R, et al. Ritanserin, imipramine, and placebo in the treatment of dysthymic disorder. J Clin Psychopharmacol 1993;13:409-414.
19. Howland RH. Pharmacotherapy of dysthymia a review. J Clin Psychopharmacol. 1991;11:83-92.
20. Harrison WM, Stewart JW. Pharmacotherapy of dysthymia. Psychiatr Ann. 1993;23:638-648.
21. Spitzer RL, Williams JBW, Gibbon M. Instruction Manual for the Structured Clinical Interview for DSM-III-R (SCID. 4/1/87 Revision). New York, NY: Biometrics Research Division, New York State Psychiatric Institute; 1987.
22. Spitzer RL, Williams JBW, Gibbon M. Instruction Manual for the Structured Clinical Interview for DSM-III-R Personality Disorders (SCID-II, 10/15/86). New York, NY: Biometrics Research Division, New York State Psychiatric Institute; 1987.
23. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
24. McGlashan T, ed. The Documentation of Clinical Psychotropic Drug Trials. Rockville, Md: National Institute of Mental Health; 1973.
25. Montgomery SA, Asberg M. New depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382.
26. Derogatis LR, Lipman RS, Rickels K, Ulenthuth EH, Covi L. The Hopkins Symptom Check List (HSCL): a self-report symptom inventory. Behav Sci. 1974;19:1-15.
27. Rush AJ, Giles DE, Schlesser MA, et al The Inventory for Depressive Symptomatology (IDS): preliminary findings Psychiatr Res. 1986;18:65-87.
28. Rush AJ, Hiser W, Giles DE. A comparison of sell-reported vs. clinician-rated symptoms in major depression. J Clin Psychiatry. 1987;48:246-248.
29. Weissman MM, Bothwell S. Assessment of social adjustment by patient selfreport. Arch Gen Psychiatry. 1976;33:111-1115.
30. Shapiro R, Keller M. Longitudinal Interval Follow-up Evaluation (LIFE). Boston. Mass: Lindemann Mental Health Center; 1979.
31. Kocsis JH, et al. Double-blind treatment comparison of sertraline. imipramine, and placebo in the treatment of dysthymia: psychosodal outcomes Am J Psychiatry. In press.
32. Frank E, Prien RF, Jarrett RB. et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder: remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 1991;48:851-855.
33. Kocsis JH, Frances AJ, Voss C. Imipramine for treatment of chronic depression. Arch Gen Psychiatry 1988;45:253-257
34. Nardi E, Capponi R, Costa DA, et al Moclobemide compared with imipramine in the treatment of chronic depression (dysthymia DSM-III-R) a double-blind placebo controlled trial. Clin Neunpharmacol. 1992;15(suppl 1):430A-434A.
35. Keller MB, Harrison W, Fawcett JA, et al. Treatment of chronic depression with sertraline or imipramine: preliminary blinded response rates and high rates of undertreatment in the community Psychopharm Bull. 1995;31:205-212
36. Feighner JP, Boyer WF. Paroxetine in the treatment of depression: a comparison with imipramine and placebo J Clin Psychiatry. 1992;53(suppl 2):44-47.
37. Bremner JD. Fluoxetine in depressed patients: a comparison with imipramine. J Clin Psychiatry. 1994;45:414.
38. Cohn JB, Wilcox C. A comparison of fluoxetine. imipramine, and placebo in patients with major depressive disorder. J Clin Psychiatry 1985;46:26.
39. Stewart JW, McGrath PJ, Quitkin FM. Relevance of DSM-III depressive subtype and chronicity to antidepressant efficacy in atypical depression. Arch Gen Psychiatry. 1989;46:1080-1087.
40. Kocsis JH, Sutton BM, Frances AJ. Long-term follow-up of chronic depression treated with imipramine. J Clin Psychiatry. 1991;52:56-59.
41. Reimherr FW, Byerly WF, Ward MF, et al. Sertraline. a selective inhibitor of serotonin uptake for the treatment of outpatients with major depressive disorder. Psychopharmacol Bull. 1988;24:200-205
42. Chouinard G. A double-blind controlled clinical trial of fluoxetine and amitriptyline in the treatment of outpatients with major depressive disorder. J Clin Psychiatry. 1985;46:32-37.
43. Cohn CK, Shrivastava R, Mendels J, et al. Double-blind comparison ot sertraline and amitriptyline in elderly depressed patients J Clin Psychiatry. 1990;51(suppl 8)28-33.
44. Bakish D, Lapierre YD, Weinstein R, et al. Ritanserin, imipramine. and placebo in the treatment of dysthymic disorder. J Clin Psychopharmacol 1993;13:409-414.